A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.
This research study is looking at a new medicine called GLPG3667 for adults who have active systemic lupus erythematosus (SLE), often just called lupus. We want to find out if this medicine can help reduce lupus symptoms, how safe it is to use, and how the body processes it. During the study, some people will receive the new medicine, while others will receive a placebo – a dummy pill that looks exactly like the medicine but contains no active ingredients. This helps scientists fairly compare the effects. The study will also track any side effects and how the medicine works in the body over time. The main goal is to see how many people show an improvement in their lupus after about 8 months.
At a glance
What is this study about?
This study is all about finding new and better ways to treat lupus (systemic lupus erythematosus, or SLE). Lupus is a long-lasting condition where your body's immune system mistakenly attacks its own healthy tissues. This can lead to problems in many parts of the body, like joints, skin, kidneys, and heart. Even though there are treatments available for lupus, there's always a need for new options that might work better or have fewer side effects.
The new medicine being tested, called GLPG3667, is a tablet you take by mouth. Researchers want to understand if this medicine can help people with lupus feel better and if it can reduce how active their lupus is. They'll also be carefully checking for any side effects and how the body deals with the medicine after it's taken. Everyone in the study will play an important part in helping to improve treatments for lupus in the future.
To make sure the results are fair and reliable, this study is 'randomized' and 'double-blind'. This means that participants are randomly put into groups, and neither you nor your study doctor will know whether you're getting the new medicine or a dummy pill (placebo). This helps prevent any bias when checking to see if the medicine works.
Key takeaways
- This study is testing a new medicine (GLPG3667) for adults with lupus.
- It aims to see if the medicine reduces lupus activity and is safe.
- You might receive the new medicine or a dummy pill (placebo).
- Participation involves regular clinic visits for health checks and tests.
- The study lasts for up to 48 weeks.
- You can stop participating at any time.
Who may be eligible?
This study is looking for adults who have active systemic lupus erythematosus (SLE), also known as lupus. You must be at least 18 years old to take part. There is no upper age limit, so older adults can also participate.
Both men and women are welcome to join the study if they meet other health requirements. The study team will need to check your medical history and current health to make sure that taking part would be safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have active systemic lupus erythematosus (lupus)?
- Are you able to attend regular clinic appointments?
- Are you willing to take study medication (either GLPG3667 or placebo) as directed?
What does participation involve?
If you decide to take part, you'll be assigned to either receive the new GLPG3667 medicine or a placebo (a dummy pill, which looks identical) – you won't know which you're getting. You'll take these tablets by mouth as instructed by the study team. Over the course of the study, you'll have several visits to the clinic. These visits will involve health checks, blood tests, and discussions about how you're feeling and any changes in your lupus symptoms.
Study doctors will carefully track your lupus activity using standard measures. They'll also monitor for any side effects you might experience. The main part of the study where benefits are looked at will last for about 32 weeks, with further checks up to 48 weeks (around 11 months). The total duration of your involvement will be explained in detail by the study team.
Potential risks and benefits
Locations (6)
- —UnverifiedGermany
- —UnverifiedFrance
- —UnverifiedSpain
- —UnverifiedPoland
- —UnverifiedBulgaria
- —UnverifiedHungary
Common questions
What is lupus (SLE)?
Lupus is a condition where your body's immune system mistakenly attacks its own healthy tissues, leading to inflammation and damage in various parts of the body.
What is GLPG3667?
GLPG3667 is a new medicine in tablet form that researchers are testing to see if it can help improve lupus symptoms and activity.
What does 'double-blind' mean?
It means that neither you nor your study doctor will know whether you're receiving the new medicine or a dummy pill (placebo). This helps ensure the study results are fair.
How long will the study last for me?
The main part of the study monitoring effects is around 32 weeks, with follow-up appointments extending to about 48 weeks (almost a year).
Can I stop participating in the study at any time?
Yes, you have the right to leave the study at any point, and it will not affect your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.